OrbusNeich's Sapphire II coronary dilatation catheter is now available in the market

OrbusNeich today announced that the next-generation Sapphire II coronary dilatation catheter is now commercially available, following CE Mark (Conformite Europeenne) approval.

Sapphire II offers an ultra-low crossing profile across a broad range of configurations, including 1.0 mm diameter balloons and 150 cm shaft working length versions.  Sapphire II features a flexible, supple balloon material for slender rewrap; an XD (eXtra Durable) shaft for enhanced pushability and superb kink resistance; proprietary Hydro-X coating for lubricious crossing; and Z-Tip technology resulting in  'Zero' transition between the tip and guidewire for smooth and safe penetration of the tightest of lesions.

"I was impressed by the crossability of Sapphire II through the stent struts in a difficult left main bifurcation procedure," said Dr. Pieter Stella, head of the interventional catheterization laboratory at the University Medical Centre (UMC), Utrecht, the Netherlands.

Al Novak, OrbusNeich's chairman and CEO, said, "Sapphire II offers interventional cardiologists an exciting new technology to address the challenges of tight and complex lesions.  Sapphire II reflects OrbusNeich's continued commitment to the innovation and development of high-performance balloon catheters."

Dr. Toshiya Muramatsu, director of the cardiology department at Saiseikai Yokohamashi Tobu Hospital in Yokohama-City, Japan, added, "The thin tip and new coating applied from the tip to the shaft contribute a great deal to the crossing performance of the Sapphire II. The crossability of Sapphire II can compete just as well, if not better, than any balloon on the market.  I would not hesitate to recommend it for use in any CTO (chronic total occlusion) case."

Source:

OrbusNeich

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Mount Sinai researchers uncover genetic basis of fibromuscular dysplasia